140 related articles for article (PubMed ID: 27721325)
1. Degradable Cross-Linked Nanoassemblies as Drug Carriers for Heat Shock Protein 90 Inhibitor 17-N-Allylamino-17-demethoxy-geldanamycin.
Ponta A; Akter S; Bae Y
Pharmaceuticals (Basel); 2011 Sep; 4(10):1281-1292. PubMed ID: 27721325
[TBL] [Abstract][Full Text] [Related]
2. Formulation and in vitro evaluation of 17-allyamino-17-demethoxygeldanamycin (17-AAG) loaded polymeric mixed micelles for glioblastoma multiforme.
Saxena V; Hussain MD
Colloids Surf B Biointerfaces; 2013 Dec; 112():350-5. PubMed ID: 24012704
[TBL] [Abstract][Full Text] [Related]
3. Pharmaceutical differences between block copolymer self-assembled and cross-linked nanoassemblies as carriers for tunable drug release.
Lee HJ; Bae Y
Pharm Res; 2013 Feb; 30(2):478-88. PubMed ID: 23054094
[TBL] [Abstract][Full Text] [Related]
4. Cross-linked nanoassemblies from poly(ethylene glycol)-poly(aspartate) block copolymers as stable supramolecular templates for particulate drug delivery.
Lee HJ; Bae Y
Biomacromolecules; 2011 Jul; 12(7):2686-96. PubMed ID: 21644544
[TBL] [Abstract][Full Text] [Related]
5. The HSP90 inhibitor 17-N-allylamino-17-demethoxy geldanamycin (17-AAG) synergizes with cisplatin and induces apoptosis in cisplatin-resistant esophageal squamous cell carcinoma cell lines via the Akt/XIAP pathway.
Ui T; Morishima K; Saito S; Sakuma Y; Fujii H; Hosoya Y; Ishikawa S; Aburatani H; Fukayama M; Niki T; Yasuda Y
Oncol Rep; 2014 Feb; 31(2):619-24. PubMed ID: 24317439
[TBL] [Abstract][Full Text] [Related]
6. Abrogation of heat shock protein 70 induction as a strategy to increase antileukemia activity of heat shock protein 90 inhibitor 17-allylamino-demethoxy geldanamycin.
Guo F; Rocha K; Bali P; Pranpat M; Fiskus W; Boyapalle S; Kumaraswamy S; Balasis M; Greedy B; Armitage ES; Lawrence N; Bhalla K
Cancer Res; 2005 Nov; 65(22):10536-44. PubMed ID: 16288046
[TBL] [Abstract][Full Text] [Related]
7. Folate receptor targeted 17-allylamino-17-demethoxygeldanamycin (17-AAG) loaded polymeric nanoparticles for breast cancer.
Saxena V; Naguib Y; Hussain MD
Colloids Surf B Biointerfaces; 2012 Jun; 94():274-80. PubMed ID: 22377218
[TBL] [Abstract][Full Text] [Related]
8. VIP-grafted sterically stabilized phospholipid nanomicellar 17-allylamino-17-demethoxy geldanamycin: a novel targeted nanomedicine for breast cancer.
Onyüksel H; Mohanty PS; Rubinstein I
Int J Pharm; 2009 Jan; 365(1-2):157-61. PubMed ID: 18793708
[TBL] [Abstract][Full Text] [Related]
9. Geldanamycin and 17-allylamino-17-demethoxygeldanamycin potentiate the in vitro and in vivo radiation response of cervical tumor cells via the heat shock protein 90-mediated intracellular signaling and cytotoxicity.
Bisht KS; Bradbury CM; Mattson D; Kaushal A; Sowers A; Markovina S; Ortiz KL; Sieck LK; Isaacs JS; Brechbiel MW; Mitchell JB; Neckers LM; Gius D
Cancer Res; 2003 Dec; 63(24):8984-95. PubMed ID: 14695217
[TBL] [Abstract][Full Text] [Related]
10. Solid lipid nanoparticles as a novel formulation approach for tanespimycin (17-AAG) against leishmania infections: Preparation, characterization and macrophage uptake.
Pires VC; Magalhães CP; Ferrante M; Rebouças JS; Nguewa P; Severino P; Barral A; Veras PST; Formiga FR
Acta Trop; 2020 Nov; 211():105595. PubMed ID: 32585150
[TBL] [Abstract][Full Text] [Related]
11. Nano self-assembly of recombinant human gelatin conjugated with α-tocopheryl succinate for Hsp90 inhibitor, 17-AAG, delivery.
Won YW; Yoon SM; Sonn CH; Lee KM; Kim YH
ACS Nano; 2011 May; 5(5):3839-48. PubMed ID: 21517103
[TBL] [Abstract][Full Text] [Related]
12. Up-regulation of heat shock protein 27 induces resistance to 17-allylamino-demethoxygeldanamycin through a glutathione-mediated mechanism.
McCollum AK; Teneyck CJ; Sauer BM; Toft DO; Erlichman C
Cancer Res; 2006 Nov; 66(22):10967-75. PubMed ID: 17108135
[TBL] [Abstract][Full Text] [Related]
13. Formation of 17-allylamino-demethoxygeldanamycin (17-AAG) hydroquinone by NAD(P)H:quinone oxidoreductase 1: role of 17-AAG hydroquinone in heat shock protein 90 inhibition.
Guo W; Reigan P; Siegel D; Zirrolli J; Gustafson D; Ross D
Cancer Res; 2005 Nov; 65(21):10006-15. PubMed ID: 16267026
[TBL] [Abstract][Full Text] [Related]
14. Cotreatment with 17-allylamino-demethoxygeldanamycin and FLT-3 kinase inhibitor PKC412 is highly effective against human acute myelogenous leukemia cells with mutant FLT-3.
George P; Bali P; Cohen P; Tao J; Guo F; Sigua C; Vishvanath A; Fiskus W; Scuto A; Annavarapu S; Moscinski L; Bhalla K
Cancer Res; 2004 May; 64(10):3645-52. PubMed ID: 15150124
[TBL] [Abstract][Full Text] [Related]
15. Encapsulation of the HSP-90 Chaperone Inhibitor 17-AAG in Stable Liposome Allow Increasing the Therapeutic Index as Assessed,
Petersen ALOA; Campos TA; Dantas DADS; Rebouças JS; da Silva JC; de Menezes JPB; Formiga FR; de Melo JV; Machado G; Veras PST
Front Cell Infect Microbiol; 2018; 8():303. PubMed ID: 30214897
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of heat shock protein 90 function by 17-allylamino-17-demethoxy-geldanamycin in Hodgkin's lymphoma cells down-regulates Akt kinase, dephosphorylates extracellular signal-regulated kinase, and induces cell cycle arrest and cell death.
Georgakis GV; Li Y; Rassidakis GZ; Martinez-Valdez H; Medeiros LJ; Younes A
Clin Cancer Res; 2006 Jan; 12(2):584-90. PubMed ID: 16428504
[TBL] [Abstract][Full Text] [Related]
17. Spotlight on 17-AAG as an Hsp90 inhibitor for molecular targeted cancer treatment.
Talaei S; Mellatyar H; Asadi A; Akbarzadeh A; Sheervalilou R; Zarghami N
Chem Biol Drug Des; 2019 May; 93(5):760-786. PubMed ID: 30697932
[TBL] [Abstract][Full Text] [Related]
18. The heat shock protein 90 inhibitor, 17-allylamino-17-demethoxygeldanamycin, enhances osteoclast formation and potentiates bone metastasis of a human breast cancer cell line.
Price JT; Quinn JM; Sims NA; Vieusseux J; Waldeck K; Docherty SE; Myers D; Nakamura A; Waltham MC; Gillespie MT; Thompson EW
Cancer Res; 2005 Jun; 65(11):4929-38. PubMed ID: 15930315
[TBL] [Abstract][Full Text] [Related]
19. Molecular mechanism of 17-allylamino-17-demethoxygeldanamycin (17-AAG)-induced AXL receptor tyrosine kinase degradation.
Krishnamoorthy GP; Guida T; Alfano L; Avilla E; Santoro M; Carlomagno F; Melillo RM
J Biol Chem; 2013 Jun; 288(24):17481-94. PubMed ID: 23629654
[TBL] [Abstract][Full Text] [Related]
20. P-Glycoprotein-mediated resistance to Hsp90-directed therapy is eclipsed by the heat shock response.
McCollum AK; TenEyck CJ; Stensgard B; Morlan BW; Ballman KV; Jenkins RB; Toft DO; Erlichman C
Cancer Res; 2008 Sep; 68(18):7419-27. PubMed ID: 18794130
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
